摘要
目的:探讨不同剂量瑞舒伐他汀对老年糖尿病患者动脉硬化的影响。方法:选取血糖控制良好的老年糖尿病患者92例(糖尿病组)和老年糖耐量正常者52例(NGT组),测定并比较颈动脉内中膜厚度(IMT)、斑块及内皮功能(EDD)等。在常规降糖基础上,将糖尿病患者按服用瑞舒伐他汀的剂量分为3组:常规组(10 mg.d-1)、强化组(20 mg.d-1)和对照组(未服用他汀类药物),观察12个月后3组患者颈动脉硬化的变化。结果:与NGT组比较,糖尿病组IMT及斑块检出率明显升高。治疗后常规组IMT无明显变化,强化组明显变薄;治疗后常规组斑块面积显著减少,强化组减少更明显(P<0.05)。对照组上述指标在治疗前后无明显变化。结论:在常规降糖基础上,瑞舒伐他汀可延缓或逆转老年糖尿病患者颈动脉硬化,这可能与其调脂、抑制炎症反应及改善内皮功能有关。
Objective： To investigate the effect of rosuvastatin on carotid atherosclerosis in elderly patients with diabetes mellitus （DM）. Methods： Totally 92 DM patients with glycemic control and 52 elderly subjects with normal glucose tolerance （NGT） were compared. DM patients with 10 and 20 mg·d^-1 rosuvastatin for 12 months in addition to usual hypoglycemia medications, or with usual hypoglycemia medications alone （control group）. The carotid intima-media thickness （IMT）, carotid plaque, endothelium-dependent dilation （EDD）, serum levels of lipid, and high-sensitive C reaction protein （HsCRP） were measured and analyzed. Results： Carotid IMT and atherosclerotic plaque were higher in DM group than in NGT group. Compared with pre-treatment, IMT did not change in 10 mg·d^-1 group and significantly decreased in 20 mg. d-1 group after treatment. Plaque area significantly decreased in l0 mg·d^-1 group and decreased further in 20 mg·d^-1 group after treatment （P 〈 0.05 ）. There was no significant difference in the two carotid parameters between pre-treatment and post-treatment. Furthermore, the change in IMT was correlated with the change in HsCRP or EDD. Conclusion： Rosuvastatin can retard or decrease carotid atherosclerosis in elderly DM patients.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2011年第21期2123-2126,2138,共5页
Chinese Journal of New Drugs
关键词
老年
糖尿病
瑞舒伐他汀
内中膜厚度
斑块
elderly
diabetes mellitus
rosuvastatin
carotid intima-media thickness
plaque
